(LH) Laboratory of America - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 21.902m USD | Total Return: 17% in 12m

Stock Medical Testing, Drug Development, Health Services
Total Rating 65
Risk 93
Buy Signal 0.59
Diagnostics & Research +11.6
Health Care Services +2.5
Market Cap: 21,902m
Avg Trading Vol: 142M USD
ATR: 2.44%
Peers RS (IBD): 65.0
Risk 5d forecast
Volatility21.4%
Rel. Tail Risk-2.60%
Reward TTM
Sharpe Ratio0.54
Alpha6.53
Character TTM
Beta0.457
Beta Downside0.395
Drawdowns 3y
Max DD17.36%
CAGR/Max DD0.69
EPS (Earnings per Share) EPS (Earnings per Share) of LH over the last years for every Quarter: "2021-03": 8.79, "2021-06": 6.13, "2021-09": 6.82, "2021-12": 6.77, "2022-03": 6.11, "2022-06": 4.95, "2022-09": 4.68, "2022-12": 4.14, "2023-03": 3.82, "2023-06": 3.8, "2023-09": 3.38, "2023-12": 3.3, "2024-03": 3.68, "2024-06": 3.94, "2024-09": 3.5, "2024-12": 3.45, "2025-03": 3.84, "2025-06": 4.35, "2025-09": 4.18, "2025-12": 4.07,
EPS CAGR: -10.27%
EPS Trend: -43.2%
Last SUE: 1.87
Qual. Beats: 4
Revenue Revenue of LH over the last years for every Quarter: 2021-03: 4161.5, 2021-06: 3840.7, 2021-09: 4062.6, 2021-12: 4056.1, 2022-03: 3899.6, 2022-06: 2923, 2022-09: 2866.8, 2022-12: 3674.2, 2023-03: 3037.8, 2023-06: 3033.7, 2023-09: 3056.8, 2023-12: 3033.3, 2024-03: 3176.6, 2024-06: 3220.9, 2024-09: 3282, 2024-12: 3329.4, 2025-03: 3345.1, 2025-06: 3527.3, 2025-09: 3563.5, 2025-12: 3515.8,
Rev. CAGR: -2.73%
Rev. Trend: 29.9%
Last SUE: -1.21
Qual. Beats: 0
Description: LH Laboratory of America

Labcorp Holdings Inc. (LH) provides diagnostic and biopharmaceutical laboratory services. The companys Diagnostics Laboratories segment offers a wide range of medical tests, including blood chemistry, infectious disease panels, and genetic testing. This segment operates within the clinical laboratory industry, which processes millions of tests daily for patient diagnosis and monitoring.

The Biopharma Laboratory Services segment supports drug and medical device development. This includes clinical trial testing and companion diagnostic development, critical components of the pharmaceutical research and development pipeline. Labcorp serves a diverse client base, including pharmaceutical companies, healthcare providers, and managed care organizations.

Labcorp also provides digital tools for patients and providers, along with specimen collection services. These digital platforms streamline access to laboratory services, a growing trend in healthcare to improve patient engagement and operational efficiency. Further research on ValueRay can provide deeper insights into Labcorps financial performance and market position.

Headlines to Watch Out For
  • Diagnostic testing volume directly impacts revenue growth
  • Biopharma services contract awards drive segment performance
  • Healthcare reimbursement rates influence profitability
  • Regulatory changes in laboratory testing create compliance costs
Piotroski VR‑10 (Strict) 7.5
Net Income: 876.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.59 > 1.0
NWC/Revenue: 8.58% < 20% (prev 11.35%; Δ -2.77% < -1%)
CFO/TA 0.09 > 3% & CFO 1.64b > Net Income 876.5m
Net Debt (6.68b) to EBITDA (2.01b): 3.32 < 3
Current Ratio: 1.42 > 1.5 & < 3
Outstanding Shares: last quarter (83.2m) vs 12m ago -1.19% < -2%
Gross Margin: 28.24% > 18% (prev 0.28%; Δ 2.80k% > 0.5%)
Asset Turnover: 75.88% > 50% (prev 70.78%; Δ 5.10% > 0%)
Interest Coverage Ratio: 5.94 > 6 (EBITDA TTM 2.01b / Interest Expense TTM 224.1m)
Altman Z'' 3.37
A: 0.07 (Total Current Assets 4.02b - Total Current Liabilities 2.82b) / Total Assets 18.39b
B: 0.47 (Retained Earnings 8.64b / Total Assets 18.39b)
C: 0.07 (EBIT TTM 1.33b / Avg Total Assets 18.39b)
D: 0.88 (Book Value of Equity 8.62b / Total Liabilities 9.76b)
Altman-Z'' Score: 3.37 = A
Beneish M -2.98
DSRI: 1.01 (Receivables 2.26b/2.10b, Revenue 13.95b/13.01b)
GMI: 0.99 (GM 28.24% / 27.86%)
AQI: 1.07 (AQ_t 0.61 / AQ_t-1 0.57)
SGI: 1.07 (Revenue 13.95b / 13.01b)
TATA: -0.04 (NI 876.5m - CFO 1.64b) / TA 18.39b)
Beneish M-Score: -2.98 (Cap -4..+1) = A
What is the price of LH shares? As of April 03, 2026, the stock is trading at USD 266.81 with a total of 807,232 shares traded.
Over the past week, the price has changed by +1.99%, over one month by -4.45%, over three months by +9.04% and over the past year by +17.04%.
Is LH a buy, sell or hold? Laboratory of America has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LH.
  • StrongBuy: 13
  • Buy: 3
  • Hold: 4
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the LH price?
Wallstreet Target Price 307.7 15.3%
Analysts Target Price 307.7 15.3%
LH Fundamental Data Overview as of 31 March 2026
P/E Trailing = 25.2581
P/E Forward = 14.8368
P/S = 1.5699
P/B = 2.5141
P/EG = 1.091
Revenue TTM = 13.95b USD
EBIT TTM = 1.33b USD
EBITDA TTM = 2.01b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 695.8m USD (from shortTermDebt, last quarter)
Debt = 7.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.68b USD (from netDebt column, last quarter)
Enterprise Value = 28.58b USD (21.90b + Debt 7.21b - CCE 532.3m)
Interest Coverage Ratio = 5.94 (Ebit TTM 1.33b / Interest Expense TTM 224.1m)
EV/FCF = 23.70x (Enterprise Value 28.58b / FCF TTM 1.21b)
FCF Yield = 4.22% (FCF TTM 1.21b / Enterprise Value 28.58b)
FCF Margin = 8.64% (FCF TTM 1.21b / Revenue TTM 13.95b)
Net Margin = 6.28% (Net Income TTM 876.5m / Revenue TTM 13.95b)
Gross Margin = 28.24% ((Revenue TTM 13.95b - Cost of Revenue TTM 10.01b) / Revenue TTM)
Gross Margin QoQ = 26.18% (prev 28.77%)
Tobins Q-Ratio = 1.55 (Enterprise Value 28.58b / Total Assets 18.39b)
Interest Expense / Debt = 0.76% (Interest Expense 55.0m / Debt 7.21b)
Taxrate = 13.48% (25.7m / 190.6m)
NOPAT = 1.15b (EBIT 1.33b * (1 - 13.48%))
Current Ratio = 1.42 (Total Current Assets 4.02b / Total Current Liabilities 2.82b)
Debt / Equity = 0.84 (Debt 7.21b / totalStockholderEquity, last quarter 8.62b)
Debt / EBITDA = 3.32 (Net Debt 6.68b / EBITDA 2.01b)
Debt / FCF = 5.54 (Net Debt 6.68b / FCF TTM 1.21b)
Total Stockholder Equity = 8.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.77% (Net Income 876.5m / Total Assets 18.39b)
RoE = 10.28% (Net Income TTM 876.5m / Total Stockholder Equity 8.52b)
RoCE = 9.78% (EBIT 1.33b / Capital Employed (Equity 8.52b + L.T.Debt 5.08b))
RoIC = 8.17% (NOPAT 1.15b / Invested Capital 14.10b)
WACC = 5.87% (E(21.90b)/V(29.11b) * Re(7.59%) + D(7.21b)/V(29.11b) * Rd(0.76%) * (1-Tc(0.13)))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -1.01%
[DCF] Terminal Value 84.60% ; FCFF base≈1.16b ; Y1≈992.7m ; Y5≈768.7m
[DCF] Fair Price = 201.9 (EV 23.31b - Net Debt 6.68b = Equity 16.63b / Shares 82.4m; r=6.0% [WACC]; 5y FCF grow -17.70% → 3.0% )
EPS Correlation: -43.21 | EPS CAGR: -10.27% | SUE: 1.87 | # QB: 4
Revenue Correlation: 29.85 | Revenue CAGR: -2.73% | SUE: -1.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.74 | Chg7d=-0.003 | Chg30d=+0.128 | Revisions Net=+6 | Analysts=13
EPS current Year (2026-12-31): EPS=17.77 | Chg7d=+0.000 | Chg30d=+0.248 | Revisions Net=+14 | Growth EPS=+8.1% | Growth Revenue=+5.2%
EPS next Year (2027-12-31): EPS=19.27 | Chg7d=+0.000 | Chg30d=+0.120 | Revisions Net=+4 | Growth EPS=+8.5% | Growth Revenue=+4.7%
[Analyst] Revisions Ratio: +0.50 (9 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.0% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = +0.8% (Analyst 4.7% - Implied 4.0%)
External Resources
Dataroma Stockcircle